Expertise in
17
conditions

Dr. Radhika Rachamalla

Hematology
Vassar Brothers Medical Center
45 Reade Pl, 
Poughkeepsie, NY 
Offers Telehealth
Expertise in
17
conditions
Vassar Brothers Medical Center
45 Reade Pl, 
Poughkeepsie, NY 

Overview

Radhika Rachamalla is a Hematologist practicing medicine in Poughkeepsie, New York.

Dr. Rachamalla is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Hereditary Spherocytosis, Acute Promyelocytic Leukemia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Gastroesophageal Junction Cancer.

She is actively involved in clinical research, participating in 6 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in NY

Hospital Affiliations

Putnam Hospital Center
Northern Dutchess Hospital
Montefiore St Luke's Cornwall
Vassar Brothers Medical Center
Sharon Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Vassar Brothers Medical Center
45 Reade Pl, Poughkeepsie, NY 12601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required
Before you request

Montefiore Medical Park At Eastchester

1695 Eastchester Road, 
Bronx, NY 
 (58.8 miles away)
718-405-8504
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marina Konopleva, MD, Phd, is Professor, Oncology, Professor, Molecular Pharmacology, Director, Leukemia Program and Co-Director, Blood Cancer Institute, at Montefiore Einstein. Her clinic focus centers on treating patients with hematologic malignancies, with an emphasis on acute myeloid and acute lymphoblastic leukemia. She has additional expertise in treating patients with high-risk myelodysplastic syndrome and chronic myeloid leukemia. Dr. Konopleva is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Konopleva is currently accepting new patients.

Expertise in
15
conditions
Dr. Saad Z. Usmani
Hematology | Oncology
Expertise in
15
conditions
Dr. Saad Z. Usmani
Hematology | Oncology
Referral may be required

Memorial Sloan Kettering Bergen

225 Summit Ave, 
Montvale, NJ 
 (44.6 miles away)
973-891-2829
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Saad Usmani is a Hematologist and an Oncologist practicing medicine in Montvale, New Jersey. Dr. Usmani is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Usmani is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Memorial Sloan Kettering Bergen

225 Summit Ave, 
Montvale, NJ 
 (44.6 miles away)
973-891-2826
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Mauro is a Hematologist practicing medicine in Montvale, New Jersey. Dr. Mauro is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Leukemia, Myeloproliferative Neoplasms (MPN), Philadelphia-Negative Chronic Myeloid Leukemia, and Bone Marrow Aspiration. Dr. Mauro is currently accepting new patients.

Frequently Asked Questions about Dr. Radhika Rachamalla

How do I make an appointment with Dr. Radhika Rachamalla?

You can book an appointment with Dr. Radhika Rachamalla by calling their office at 845-483-6960. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Radhika Rachamalla a top-rated expert for Hereditary Spherocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Radhika Rachamalla is classified as an Distinguished expert for Hereditary Spherocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Radhika Rachamalla specialize in?

While Dr. Radhika Rachamalla is a Hematology, they have specific expertise in Hereditary Spherocytosis, Acute Promyelocytic Leukemia, and Monoclonal Gammopathy of Undetermined Significance (MGUS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Radhika Rachamalla accept my insurance?

Dr. Radhika Rachamalla accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 845-483-6960 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rachamalla's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 53 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile